Agronomics offers highly asymmetric cellular-agriculture exposure at a 56% NAV discount, but scarce cash, dilution and illiquid private assets make it a speculative long-term bet.
Overview
Agronomics Limited is an AIM-listed, globally diversified investment company providing liquid public-market access to early-stage cellular-agriculture and precision-fermentation businesses. Co-founded by Jim Mellon, it owns stakes in companies developing cultivated meat, animal-free proteins, contract fermentation, pet food and gene-edited crops. **The core investment case is a large discount to independently carried NAV:** June 30, 2026 net assets were £140.03 million, or £0.1293 per share, versus a reported market price of £0.0510, a 56% discount and approximately 0.39x price-to-book. Value realization depends on portfolio exits, acquisitions and IPOs rather than recurring revenue. The latest quarter showed portfolio investments of £138.51 million and cash of £1.59 million; NAV rose 1.00% quarter-on-quarter, but NAV per share fell 1.45% because shares issued for a £3.7 million SuperMeat follow-on investment increased the share count 2.54%. Near-term catalysts include Liberation Bioindustries’ 600,000-liter facility, Onego’s September 2025 FDA “no questions” GRAS outcome, Meatly’s commercial rollout and Tropic’s regulatory approvals. Canaccord retained Buy with a £0.1330 target, while wider consensus is £0.1469. The opportunity is highly speculative because liquidity, dilution and regulatory risks may keep the discount wide.